Therapeutic role of histone deacetylase inhibition in an in vitro model of Graves' orbitopathy
Molecular Medicine Reports · 26.09.2024 · 30 (6)
DOI: 10.3892/mmr.2024.13342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Medicine Reports, online erschienen am 26.09.2024. Verfasst von Hyeong Ju Byeon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Histone Deacetylase Inhibitors, Fibroblasts, Histone Deacetylases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Graves' orbitopathy (GO), a manifestation of Graves' disease, is characterized by orbital fibroblast‑induced inflammation, leading to fibrosis or adipogenesis. Histone deacetylase (HDAC) serves a central role in autoimmune diseases and fibrosis. The present study investigated HDAC inhibition in orbital fibroblasts from patients with GO to evaluate its potential as a therapeutic agent. Primary cultured orbital fibroblasts were treated with an HDAC inhibitor, panobinostat, under the stimulation of IL‑1β, TGF‑β or adipogenic medium. Inflammatory cytokines, and fibrosis‑ and adipogenesis‑related proteins were analyzed using western blotting. The effects of panobinostat on HDAC mRNA expression were measured in GO orbital fibroblasts, and specific HDACs were inhibited using small interfering RNA transfection. Panobinostat significantly reduced the IL‑1β‑induced production of inflammatory cytokines and TGF‑β‑induced production of fibrosis‑related proteins. It also suppressed adipocyte differentiation and adipogenic transcription factor production. Furthermore, it significantly attenuated HDAC7 mRNA expression in GO orbital fibroblasts. In addition, the silencing of HDAC7 led to anti‑inflammatory and anti‑fibrotic effects. In conclusion, by inhibiting HDAC7 gene expression, panobinostat may suppress the production of inflammatory cytokines, profibrotic proteins and adipogenesis in GO orbital fibroblasts. The present in vitro study suggested that HDAC7 could be a potential therapeutic target for inhibiting the inflammatory, adipogenic and fibrotic mechanisms of GO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea.
- Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Division of Oculofacial Plastic and Reconstructive Surgery, Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA 92037, USA.
Zitieren
APA
Byeon, H. J., Choi, S. H., Kikkawa, D. O., Ko, J., & Yoon, J. S. (2024). Therapeutic role of histone deacetylase inhibition in an in vitro model of Graves' orbitopathy. Molecular Medicine Reports, 30(6). https://doi.org/10.3892/mmr.2024.13342
Vancouver
Byeon HJ, Choi SH, Kikkawa DO, Ko J, Yoon JS. Therapeutic role of histone deacetylase inhibition in an in vitro model of Graves' orbitopathy. Molecular Medicine Reports. 2024;30(6). doi:10.3892/mmr.2024.13342
BibTeX
@article{Byeon2024,
author = {Byeon, Hyeong Ju and Choi, Soo Hyun and Kikkawa, Don O and Ko, Jaesang and Yoon, Jin Sook},
title = {Therapeutic role of histone deacetylase inhibition in an in vitro model of Graves' orbitopathy},
journal = {Molecular Medicine Reports},
year = {2024},
volume = {30},
number = {6},
doi = {10.3892/mmr.2024.13342}
}
EUVIMED